Voleon Capital Management LP Acquires 83,015 Shares of Pfizer Inc. $PFE

Key Points

• Voleon Capital Management LP significantly increased its holdings in Pfizer Inc. by 103.9% during the first quarter, acquiring an additional 83,015 shares, bringing its total to 162,924 shares valued at $4.12 million.
• Pfizer reported a 10.3% increase in revenue year-over-year, with earnings per share of $0.78, exceeding analysts' expectations and leading to a positive outlook forecast for FY 2025 at 2.900-3.100 EPS.
• The company has announced a quarterly dividend of $0.43, translating to an annualized dividend yield of 6.9%, while maintaining a dividend payout ratio of 91.49%.

Voleon Capital Management LP boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 103.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,924 shares of the biopharmaceutical company's stock after buying an additional 83,015 shares during the period. Voleon Capital Management LP's holdings in Pfizer were worth $4,128,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. grew its stake in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after buying an additional 4,629,976 shares in the last quarter. Northern Trust Corp grew its stake in Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after buying an additional 3,943,397 shares in the last quarter. Amundi grew its stake in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after buying an additional 15,758,846 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Pfizer by 3.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after purchasing an additional 1,333,740 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after purchasing an additional 838,198 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.33 during mid-day trading on Monday, reaching $24.55. 49,188,016 shares of the company were exchanged, compared to its average volume of 34,669,424. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $139.56 billion, a PE ratio of 13.06, a PEG ratio of 0.88 and a beta of 0.55. The company's 50 day moving average price is $24.85 and its 200 day moving average price is $24.32.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank reduced their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.